sub:assertion {
  d:DB05483 v:identifier "DB05483" ;
    v:namespace "drugbank" ;
    v:uri "http://bio2rdf.org/drugbank:DB05483" ;
    v:x-identifiers.org <http://identifiers.org/drugbank/DB05483> ;
    dv:drugbank-id "DB05483" ;
    dv:x-cas <http://bio2rdf.org/cas:> ;
    dct:description "PCL-016  or Picolinic acid drug substance is a pyridine carboxylate metabolite of tryptophan. It acts as an anti-infective and immunomodulator and is produced in approximately 25-50 mg quantities by the body on a daily basis through the breakdown of tryptophan. PCL-016 plays a key role in zinc transport. As a therapeutic agent, the molecule works by binding to zinc finger proteins (ZFPs) in a way that changes their structures and disrupts zinc binding, inhibiting function. ZFPs are involved in viral replication and packaging as well as normal cell homeostatic functions. Picolinic acid has been shown to be an anti-viral in vitro and in vivo, and sometimes works in conjunction with other cytokines such as interferon gamma to affect immune responses. Acne vulgaris, herpes and other viral infections therefore pose potential therapeutic targets of PCL-016."@en ;
    dct:identifier "drugbank:DB05483" ;
    dct:title "PCL-016"@en ;
    a dv:Drug ;
    rdfs:label "PCL-016 [drugbank:DB05483]"@en ;
    rdfs:seeAlso <http://www.drugbank.ca/drugs/DB05483> .
}